What is the appropriate dosing and monitoring strategy for digoxin and amiodarone in a patient with heart failure presenting with fast atrial fibrillation with rapid ventricular response?

Intravenous Digoxin or Amiodarone for Acute Rate Control in Atrial Fibrillation with Heart Failure

For patients with atrial fibrillation with rapid ventricular response and heart failure, intravenous digoxin or amiodarone are both Class I recommended first-line agents for acute rate control 1, 2, 3.

Acute Management Strategy

Initial Agent Selection

Both drugs are equally recommended by guidelines, but your choice should be guided by:

Choose IV Digoxin when:

• Patient has preserved ejection fraction (HFpEF) or compensated heart failure
• Slower onset of action (60+ minutes) is acceptable
• Patient is sedentary or at rest
• No concurrent amiodarone therapy

Choose IV Amiodarone when:

• More rapid rate control is needed (onset <30 minutes) 4
• Other rate control measures have failed (Class IIa) 1, 2
• Patient has decompensated heart failure with reduced ejection fraction (HFrEF)
• Concurrent rhythm control strategy is being considered

Dosing Regimens

IV Digoxin Loading:

• Loading dose: 0.25 mg IV every 2 hours, up to maximum 1.5 mg over 24 hours 5, 6
• Onset: 60 minutes or more 5
• Maintenance: 0.125-0.375 mg daily IV or oral 5, 6
• Target serum concentration: 0.5-0.9 ng/mL (NOT higher) 7, 8

IV Amiodarone Loading:

• Loading dose: 150 mg IV over 10 minutes 5, 4, 6
• Maintenance infusion: 1 mg/min for 6 hours, then 0.5 mg/min for 18 hours 5, 4, 9
• Total first 24 hours: Approximately 1000 mg 9
• Onset: Less than 30 minutes 4

Critical Monitoring Requirements

For Digoxin:

Before initiating:

• Serum creatinine and calculate creatinine clearance (CrCl) 8
• Serum potassium and magnesium (correct if low) 8
• Check for concurrent amiodarone use

Dose adjustments required:

• If CrCl <30 mL/min: Reduce to 0.0625 mg daily 10
• If on concurrent amiodarone: Reduce digoxin dose by 30-50% 8, 10
• Age >70 years: Start with 0.125 mg daily 8
• Low body weight: Use lower doses 8

Ongoing monitoring:

• Serum digoxin levels if toxicity suspected or high-risk patients (elderly women, renal impairment, low body weight) 7, 8
• Target trough level: 0.5-0.9 ng/mL (levels >1.2 ng/mL associated with increased mortality) 7, 6
• Electrolytes (K+, Mg2+) periodically 8

For Amiodarone:

Before initiating:

• Blood pressure monitoring (risk of hypotension) 5, 4
• Continuous ECG monitoring 4
• Liver function tests at baseline 11

During infusion:

• Must use central venous catheter if concentration >2 mg/mL 9
• Use volumetric infusion pump (NOT drop counters) 9
• Monitor for hypotension and bradycardia 5, 4
• Maximum infusion rate: 30 mg/min 9

Ongoing monitoring:

• Thyroid function, liver enzymes, pulmonary function if continued beyond acute setting 4

Common Pitfalls and Contraindications

Absolute Contraindications:

Both agents:

• Pre-excitation syndromes (WPW) - may paradoxically accelerate ventricular response 1
• Advanced AV block without pacemaker 5, 11

Digoxin specifically:

• Should NOT be used as sole agent in paroxysmal AF 1
• Avoid in acute MI setting (may increase oxygen demand) 8

Amiodarone specifically:

• Recent acute coronary syndrome (for rhythm control, but caution for rate control) 12

Drug Interactions:

Digoxin levels INCREASED by:

• Amiodarone (reduce digoxin by 30-50%) 8, 10
• Verapamil, quinidine, spironolactone 8
• Macrolide antibiotics (erythromycin, clarithromycin) 8

Avoid combining:

• IV calcium with digoxin (risk of serious arrhythmias) 8
• Multiple AV nodal blocking agents without careful monitoring 1

Transition to Oral Therapy

Digoxin:

• Can transition directly to oral maintenance dosing
• Typical maintenance: 0.125 mg daily for most patients 7, 8
• 0.0625 mg daily if CrCl <30 mL/min or on amiodarone 10

Amiodarone:

• If IV <1 week: 800-1600 mg/day oral
• If IV 1-3 weeks: 600-800 mg/day oral
• If IV >3 weeks: 400 mg/day oral 4
• Then taper to 200 mg daily maintenance 11, 4

Combination Therapy

A combination of digoxin with a beta-blocker (or non-dihydropyridine calcium channel blocker in HFpEF) is Class IIa reasonable for controlling rate at rest and during exercise 1. However, dose must be modulated to avoid excessive bradycardia 1.

Critical caveat: In decompensated HF, IV beta-blockers and non-dihydropyridine calcium channel blockers are contraindicated (Class III Harm) 2, 3, making digoxin or amiodarone the only safe IV options.